

# Jolie Ringash

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5818051/publications.pdf>

Version: 2024-02-01

224  
papers

11,848  
citations

24978

57  
h-index

30848

102  
g-index

224  
all docs

224  
docs citations

224  
times ranked

12866  
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>Out-of-pocket</scp> costs associated with head and neck cancer treatment. Cancer Reports, 2022, 5, e1528.	0.6	10
2	Treatment outcomes and survival following definitive (chemo)radiotherapy in <scp>HPV</scp>-positive oropharynx cancer: Large-scale comparison of <scp>DAHANCA</scp> vs <scp>PMH</scp> cohorts. International Journal of Cancer, 2022, 150, 1329-1340.	2.3	8
3	Canadian Perspectives on Radiation Oncologist Workforce Planning and the Job Market. International Journal of Radiation Oncology Biology Physics, 2022, 112, 282-284.	0.4	3
4	Short and Simple Palliative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 112, 583-584.	0.4	0
5	Employment Outcomes for Canadian Radiation Oncology Graduates: 2020 Assessment and Longitudinal Trends. Advances in Radiation Oncology, 2022, 7, 100915.	0.6	2
6	Psychometric properties of patient-reported outcome measures for dysphagia in head and neck cancer: a systematic review protocol using COSMIN methodology. Systematic Reviews, 2022, 11, 27.	2.5	8
7	Impact of the COVID-19 Pandemic on Canadian Radiation Oncology Practices. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	0
8	Development and Validation of an Oral Cavity Cancer Outcomes Prediction Score Incorporating Patient-Derived Xenograft Engraftment. JAMA Otolaryngology - Head and Neck Surgery, 2022, , .	1.2	1
9	Clinical presentation and outcome of human papillomavirus-positive nasopharyngeal carcinoma in a North American cohort. Cancer, 2022, 128, 2908-2921.	2.0	10
10	Osteoradionecrosis in head and neck cancer patients: Risk factors and comparison of grading systems.. Journal of Clinical Oncology, 2022, 40, e18057-e18057.	0.8	0
11	Prognostic factors in sinonasal cancers: A multicenter pooled analysis.. Journal of Clinical Oncology, 2022, 40, 6092-6092.	0.8	0
12	Pre-treatment psychoeducational intervention and outcomes in head and neck cancer patients undergoing radiotherapy. Supportive Care in Cancer, 2021, 29, 1643-1652.	1.0	8
13	Pre- and Post-Radiotherapy Radiologic Nodal Features and Oropharyngeal Cancer Outcomes. Laryngoscope, 2021, 131, E1162-E1171.	1.1	9
14	Short-term and long-term unstimulated saliva flow following unilateral vs bilateral radiotherapy for oropharyngeal carcinoma. Head and Neck, 2021, 43, 456-466.	0.9	1
15	Healthcare resource utilization following unilateral versus bilateral radiation therapy for oropharyngeal carcinoma. Radiotherapy and Oncology, 2021, 156, 95-101.	0.3	2
16	Chemoradiotherapy Using Carboplatin plus Paclitaxel versus Cisplatin plus Fluorouracil for Esophageal or Gastroesophageal Junction Cancer. Oncology, 2021, 99, 49-56.	0.9	9
17	Non-operative management for oral cavity carcinoma: Definitive radiation therapy as a potential alternative treatment approach. Radiotherapy and Oncology, 2021, 154, 70-75.	0.3	23
18	Presence and duration of feeding tube in a 5-year cohort of patients with head and neck cancer treated with curative intensity-modulated radiation therapy. Head and Neck, 2021, 43, 1610-1620.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma. <i>Oral Oncology</i> , 2021, 114, 105167.	0.8	11
20	Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. <i>Radiotherapy and Oncology</i> , 2021, 156, 120-126.	0.3	19
21	Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). <i>British Journal of Cancer</i> , 2021, 124, 1543-1551.	2.9	19
22	Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 157, 255-262.	0.3	4
23	Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).. <i>Journal of Clinical Oncology</i> , 2021, 39, 6010-6010.	0.8	20
24	Variability in Steroid Prophylaxis for Radiation-Induced Pain Flare: Practice of Canadian Radiation Oncologists. <i>Journal of Palliative Medicine</i> , 2021, 24, 965-966.	0.6	0
25	Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario. <i>Canadian Liver Journal</i> , 2021, 4, 257-274.	0.3	4
26	Outcome and treatment toxicity in east-indian versus white-canadian patients with oral cavity cancer following postoperative (chemo-)radiotherapy delivered under similar multidisciplinary care: A propensity-matched cohort study. <i>Oral Oncology</i> , 2021, 120, 105419.	0.8	4
27	“œt’s good for the soul:” Perceptions of a formal junior faculty mentorship program at a large academic cancer centre. <i>Radiotherapy and Oncology</i> , 2021, 162, 119-123.	0.3	2
28	Have We Tipped the Balance in HPV-Associated Oropharyngeal Cancer?: The Patient-Experience Side of the De-Escalation Balance Scale. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 887-889.	0.4	0
29	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. <i>Radiotherapy and Oncology</i> , 2021, 165, 94-102.	0.3	22
30	Regional Recurrences and Hyams Grade in Esthesioneuroblastoma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2021, 82, 608-614.	0.4	3
31	The Prevalence and Determinants of Return to Work in Nasopharyngeal Carcinoma Survivors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 134-145.	0.4	15
32	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. <i>Radiotherapy and Oncology</i> , 2020, 144, 13-22.	0.3	30
33	Patient-Reported Symptoms for Esophageal Cancer Patients Undergoing Curative Intent Treatment. <i>Annals of Thoracic Surgery</i> , 2020, 109, 367-374.	0.7	18
34	Sexual satisfaction in nasopharyngeal carcinoma survivors: Rates and determinants. <i>Oral Oncology</i> , 2020, 109, 104865.	0.8	4
35	In Regard to Yerramilli et al’s “œPalliative Radiotherapy for Oncologic Emergencies in the Setting of COVID-19: Approaches to Balancing Risks and Benefits” Advances in Radiation Oncology, 2020, 5, 595-596.	0.6	6
36	Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion. <i>European Journal of Cancer</i> , 2020, 134, 41-51.	1.3	46

#	ARTICLE	IF	CITATIONS
37	Quality of Life, Toxicity and Unmet Needs in Nasopharyngeal Cancer Survivors. <i>Frontiers in Oncology</i> , 2020, 10, 930.	1.3	31
38	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. <i>Cancer</i> , 2020, 126, 3426-3437.	2.0	42
39	Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire. <i>Cancer</i> , 2020, 126, 4042-4050.	2.0	25
40	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , 2020, 105, 104666.	0.8	8
41	Variation in treatment patterns and outcomes for resected esophageal cancer at designated thoracic surgery centers.. <i>Journal of Clinical Oncology</i> , 2020, 38, 343-343.	0.8	0
42	A scoping review of rehabilitation interventions for survivors of head and neck cancer. <i>Disability and Rehabilitation</i> , 2019, 41, 2093-2107.	0.9	28
43	The prevalence and determinants of return to work in head and neck cancer survivors. <i>Supportive Care in Cancer</i> , 2019, 27, 539-546.	1.0	45
44	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2019, 118, 112-120.	1.3	14
45	Readmission rates following esophageal cancer resection are similar at regionalized and non-regionalized centers: A population-based cohort study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 934-942.e2.	0.4	5
46	Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy. <i>Oral Oncology</i> , 2019, 97, 124-130.	0.8	2
47	Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirus-Mediated Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1017-1027.	0.4	50
48	Validation of distant metastases risk-groups in oral cavity squamous cell carcinoma patients treated with postoperative intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 134, 10-16.	0.3	8
49	Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG) Tj ETQq1 1 0.784314 r gBT /Ov 6.3 879	0.3	8
50	Predictors of Early Recurrence Prior to Planned Postoperative Radiation Therapy for Oral Cavity Squamous Cell Carcinoma and Outcomes Following Salvage Intensified Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 363-373.	0.4	38
51	A cross sectional study in cognitive and neurobehavioral impairment in long-term nasopharyngeal cancer survivors treated with intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 131, 179-185.	0.3	38
52	Role of the oral and gut microbiota as a biomarker in locoregionally advanced oropharyngeal squamous cell carcinoma (ROMA LA-OPSCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6045-6045.	0.8	5
53	Development and validation of a prediction-score model for distant metastases in major salivary gland carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6085-6085.	0.8	1
54	Stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion.. <i>Journal of Clinical Oncology</i> , 2019, 37, 428-428.	0.8	0

#	ARTICLE	IF	CITATIONS
55	Early stage hepatocellular carcinoma treated with stereotactic body radiation therapy: A pooled analysis from two North American institutions.. Journal of Clinical Oncology, 2019, 37, 350-350.	0.8	11
56	Impact of adjuvant chemotherapy and cumulative cisplatin dose in locally advanced nasopharyngeal carcinoma (LA-NPC) treated with definitive chemoradiotherapy.. Journal of Clinical Oncology, 2019, 37, 6046-6046.	0.8	0
57	Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1107-1116.	0.4	57
58	Baseline Albumin-Bilirubin (ALBI) Score in Western Patients With Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy (SBRT). International Journal of Radiation Oncology Biology Physics, 2018, 101, 900-909.	0.4	37
59	Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 847-856.	0.4	31
60	Partial Laryngeal IMRT for T2N0 Glottic Cancer: Impact of Image Guidance and Radiation Therapy Intensification. International Journal of Radiation Oncology Biology Physics, 2018, 102, 941-949.	0.4	17
61	Evaluation of a rehabilitation planning consult for survivors of head and neck cancer. Head and Neck, 2018, 40, 1415-1424.	0.9	5
62	Dysphagia Treatment for Patients With Head and Neck Cancer Undergoing Radiation Therapy: A Meta-analysis Review. International Journal of Radiation Oncology Biology Physics, 2018, 101, 421-444.	0.4	71
63	Informational Needs of Head and Neck Cancer Patients. Journal of Cancer Education, 2018, 33, 847-856.	0.6	28
64	Work-related experiences of head and neck cancer survivors: an exploratory and descriptive qualitative study. Disability and Rehabilitation, 2018, 40, 1252-1258.	0.9	31
65	Head and Neck Cancer Survivorship: Learning the Needs, Meeting the Needs. Seminars in Radiation Oncology, 2018, 28, 64-74.	1.0	97
66	Staging and surgical approaches in gastric cancer: A systematic review. Cancer Treatment Reviews, 2018, 63, 104-115.	3.4	98
67	Impact of neoadjuvant radiation on margins for non-squamous cell carcinoma sinonasal malignancies. Laryngoscope, 2018, 128, 2796-2803.	1.1	10
68	Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 340-352.	0.4	99
69	Prevalence, prognosis, and treatment implications of retropharyngeal nodes in unknown primary head and neck carcinoma. Oral Oncology, 2018, 82, 162-167.	0.8	9
70	Head and Neck Cancer Survivorship Care: A Review of the Current Guidelines and Remaining Unmet Needs. Current Treatment Options in Oncology, 2018, 19, 44.	1.3	58
71	The ongoing challenge of large anal cancers: prospective long term outcomes of intensity-modulated radiation therapy with concurrent chemotherapy. Oncotarget, 2018, 9, 20439-20450.	0.8	21
72	Effect of p16 Status on the Quality-of-Life Experience During Chemoradiation for Locally Advanced Oropharyngeal Cancer: A Substudy of Randomized Trial Trans-Tasman Radiation Oncology Group (TROG) 02.02 (HeadSTART). International Journal of Radiation Oncology Biology Physics, 2017, 97, 678-686.	0.4	41

#	ARTICLE	IF	CITATIONS
73	Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6). <i>European Journal of Cancer</i> , 2017, 72, 192-199.	1.3	18
74	Predictors of Liver Toxicity Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 939-946.	0.4	94
75	Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 186-195.	0.4	27
76	Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25 Years Later. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 159-169.	0.4	61
77	Phase I trial of radiation therapy and sorafenib in unresectable liver metastases. <i>Radiotherapy and Oncology</i> , 2017, 123, 234-239.	0.3	20
78	Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy. <i>Practical Radiation Oncology</i> , 2017, 7, e331-e337.	1.1	13
79	Quality of Life in Head and Neck Cancer: Where We Are, and Where We Are Going. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 662-666.	0.4	25
80	Long-Term Outcomes of Phase 1 and 2 Studies of SBRT for Hepatic Colorectal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 388-395.	0.4	68
81	Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 858-867.	0.4	19
82	Morphologic and topographic radiologic features of human papillomavirus-related and "unrelated" oropharyngeal carcinoma. <i>Head and Neck</i> , 2017, 39, 1524-1534.	0.9	37
83	Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy. <i>Cancer</i> , 2017, 123, 3691-3700.	2.0	99
84	Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 368.	1.2	19
85	Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 220.	3.4	64
86	Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 225-231.	0.3	33
87	Outcome following radiotherapy for head and neck basal cell carcinoma with "aggressive" features. <i>Oral Oncology</i> , 2017, 72, 157-164.	0.8	15
88	Partner's survivorship care needs: An analysis in head and neck cancer patients. <i>Oral Oncology</i> , 2017, 71, 113-121.	0.8	12
89	The "rocky" treatment course: identifying a high-risk subgroup of head and neck cancer patients for supportive interventions. <i>Supportive Care in Cancer</i> , 2017, 25, 719-727.	1.0	5
90	Comparison of chemoradiotherapy (CRT) using carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or gastroesophageal junctional (GEJ) cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 4053-4053.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Long-Term Quality of Life of Retroperitoneal Sarcoma Patients Treated with Pre-Operative Radiotherapy and Surgery. <i>Cureus</i> , 2017, 9, e1764.	0.2	10
92	Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.. <i>Journal of Clinical Oncology</i> , 2017, 35, 189-189.	0.8	0
93	Comparison of chemoradiotherapy (CRT) with carboplatin/paclitaxel (CP) versus cisplatin/5-FU (CF) for esophageal or junctional cancer: Experience from the Princess Margaret Cancer Centre.. <i>Journal of Clinical Oncology</i> , 2017, 35, 126-126.	0.8	0
94	Outcomes for patients ≥75 years with localized gastroesophageal cancer: Experience from the Princess Margaret Cancer Centre.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10037-10037.	0.8	0
95	Outcomes after reirradiation for recurrent nasopharyngeal carcinoma: North American experience. <i>Head and Neck</i> , 2016, 38, E1102-9.	0.9	39
96	Prevalence and nature of survivorship needs in patients with head and neck cancer. <i>Head and Neck</i> , 2016, 38, 1097-1103.	0.9	64
97	Clinical outcomes in patients with T4 laryngeal cancer treated with primary radiotherapy versus primary laryngectomy. <i>Head and Neck</i> , 2016, 38, E2035-40.	0.9	29
98	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016, 67, 174-182.	1.3	75
99	Improving Head and Neck Cancer Outcomes: Technology, Used Wisely. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 489-492.	0.4	3
100	Assessing head and neck cancer patient preferences and expectations: A systematic review. <i>Oral Oncology</i> , 2016, 62, 44-53.	0.8	39
101	E-Mail Communication Practices and Preferences Among Patients and Providers in a Large Comprehensive Cancer Center. <i>Journal of Oncology Practice</i> , 2016, 12, 676-684.	2.5	13
102	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 994-1002.	0.4	3
103	Reply to N. Osazuwa-Peters et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1152-1152.	0.8	0
104	Quality of Life and Value Considerations in Head and Neck Proton Beam Therapy: The Holy Grail at Last, or the Quest Continues?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 40-42.	0.4	5
105	Salivary duct carcinoma: Treatment, outcomes, and patterns of failure. <i>Head and Neck</i> , 2016, 38, E820-6.	0.9	82
106	Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. <i>Oral Oncology</i> , 2016, 54, 75-80.	0.8	56
107	Is Pilocarpine Effective in Preventing Radiation-Induced Xerostomia? A Systematic Review and Meta-analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 503-511.	0.4	32
108	Healthcare providers didn't actually know there was such a thing as rehab for survivor, family, and clinician perceptions of rehabilitation following treatment for head and neck cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 1449-1453.	1.0	36



#	ARTICLE	IF	CITATIONS
109	Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 580-587.	0.4	103
110	The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv391.	3.0	28
111	Retrospective assessment of patterns of recurrence relative to radiotherapy volumes for adjuvant conformal chemoradiotherapy in gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 887-893.	2.7	4
112	E3311 trial of transoral surgery for oropharynx cancer: Implementation of a novel surgeon credentialing and quality assurance process.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6054-6054.	0.8	6
113	Partnerâ€™s survivorship care needs: Multivariable analysis in head and neck cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 120-120.	0.8	1
114	Prospective evaluation of quality of life (QOL) during a phase I/II study of adjuvant chemotherapy with image-guided high-precision radiotherapy for completely resected gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 164-164.	0.8	2
115	Advice about Work-Related Issues to Peers and Employers from Head and Neck Cancer Survivors. <i>PLoS ONE</i> , 2016, 11, e0152944.	1.1	19
116	Quality of Life in Head and Neck Cancer Patients. , 2016, , 809-820.		2
117	Patient recruitment in an oligometastases trial: experience from a phase II study of 5 fraction stereotactic body radiation therapy (SBRT).. <i>Journal of Clinical Oncology</i> , 2016, 34, e14050-e14050.	0.8	0
118	Clinical relevance of lymph node ratio in resected oral cavity squamous cell carcinoma in patients with N2 disease.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6019-6019.	0.8	0
119	The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. <i>European Journal of Cancer</i> , 2015, 51, 2808-2819.	1.3	105
120	Outcomes toolbox for head and neck cancer research. <i>Head and Neck</i> , 2015, 37, 425-439.	0.9	43
121	Assessment of the Disabilities of the Arm, Shoulder, and Hand (DASH) questionnaire for use in patients after neck dissection for head and neck cancer. <i>Head and Neck</i> , 2015, 37, 234-242.	0.9	18
122	Extra-pulmonary small cell carcinoma in the head and neck setting: The role of prophylactic cranial irradiation. <i>Oral Oncology</i> , 2015, 51, e57-e59.	0.8	5
123	No evidence for improved TORS post-treatment feeding tube dependency rate relative to standard therapy in early stage oropharyngeal cancer. <i>Oral Oncology</i> , 2015, 51, e67.	0.8	0
124	Gastric cancer recurrence after resection and adjuvant chemoradiation. <i>Journal of Radiation Oncology</i> , 2015, 4, 79-85.	0.7	1
125	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM Stage and Prognostic Groups for Human Papillomavirusâ€“Related Oropharyngeal Carcinomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 836-845.	0.8	345
126	A systematic review of quality of life in head and neck cancer treated with surgery with or without adjuvant treatment. <i>Oral Oncology</i> , 2015, 51, 888-900.	0.8	123



#	ARTICLE	IF	CITATIONS
127	Changes Experienced in Quality of Life for Skull Base Surgical Patients: A Qualitative Case Study. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2015, 76, 129-144.	0.4	0
128	Development and preliminary evaluation of a rehabilitation consult for survivors of head and neck cancer: an intervention mapping protocol. <i>Implementation Science</i> , 2015, 10, 6.	2.5	14
129	Survivorship and Quality of Life in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3322-3327.	0.8	162
130	Randomized Trial Comparing Radiologic Pigtail Gastrostomy and Peroral Image-Guided Gastrostomy: Intra- and Postprocedural Pain, Radiation Exposure, Complications, and Quality of Life. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1680-1686.	0.2	15
131	Prospective Longitudinal Assessment of Quality of Life for Liver Cancer Patients Treated With Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 16-25.	0.4	63
132	Joint modeling of longitudinal health-related quality of life data and survival. <i>Quality of Life Research</i> , 2015, 24, 795-804.	1.5	21
133	Integrating health-related quality of life findings from randomized clinical trials into practice: an international study of oncologists' perspectives. <i>Quality of Life Research</i> , 2015, 24, 1317-1325.	1.5	21
134	Outcomes of intensity-modulated radiotherapy versus conventional radiotherapy for hypopharyngeal cancer. <i>Head and Neck</i> , 2015, 37, 655-661.	0.9	30
135	Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer stratified by human papillomavirus status. <i>Cancer</i> , 2015, 121, 545-555.	2.0	133
136	Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 6000-6000.	0.8	17
137	Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (̂) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC). <i>Journal of Clinical Oncology</i> , 2015, 33, 6020-6020.	0.8	7
138	Email communication practices and preferences among patients and providers in a large comprehensive cancer center. <i>Journal of Clinical Oncology</i> , 2015, 33, 6519-6519.	0.8	0
139	Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248). <i>Journal of Clinical Oncology</i> , 2015, 33, 6853-6853.	0.8	0
140	Evaluation of shoulder disability questionnaires used for the assessment of shoulder disability after neck dissection for head and neck cancer. <i>Head and Neck</i> , 2014, 36, 1453-1458.	0.9	8
141	Scoping review of the literature on shoulder impairments and disability after neck dissection. <i>Head and Neck</i> , 2014, 36, 299-308.	0.9	40
142	A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. <i>Cancer</i> , 2014, 120, 302-311.	2.0	168
143	Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: A systematic review. <i>Oral Oncology</i> , 2014, 50, 254-262.	0.8	94
144	Outcome following IMRT for T2 glottic cancer: the potential impact of image-guidance protocols on local control. <i>Journal of Radiation Oncology</i> , 2014, 3, 267-275.	0.7	6

#	ARTICLE	IF	CITATIONS
145	Facing head and neck cancer deaths head on: Lessons for survival. <i>Cancer</i> , 2014, 120, 1446-1449.	2.0	4
146	Prospective Evaluation of Acute Toxicity and Quality of Life After IMRT and Concurrent Chemotherapy for Anal Canal and Perianal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 587-594.	0.4	88
147	Quality of Life in a Prospective, Multicenter Phase 2 Trial of Neoadjuvant Full-Dose Gemcitabine, Oxaliplatin, and Radiation in Patients With Resectable or Borderline Resectable Pancreatic Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 270-277.	0.4	35
148	Quality of life in patients with KRAS wild-type colorectal cancer. <i>Cancer</i> , 2014, 120, 181-189.	2.0	18
149	Technical challenges of sparing infrahyoid swallowing organs at risk in oropharynx squamous cell cancer treated with IMRT. <i>Medical Dosimetry</i> , 2014, 39, 146-151.	0.4	2
150	Assessment of nonrespiratory stomach motion in healthy volunteers in fasting and postprandial states. <i>Practical Radiation Oncology</i> , 2014, 4, 288-293.	1.1	7
151	Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. <i>Radiotherapy and Oncology</i> , 2014, 111, 412-417.	0.3	177
152	Patient preferences for oropharyngeal cancer treatment de-escalation. <i>Head and Neck</i> , 2013, 35, 151-159.	0.9	55
153	Physical morbidity by surgical approach and tumor location in skull base surgery. <i>Head and Neck</i> , 2013, 35, 493-499.	0.9	24
154	Temporal Nodal Regression and Regional Control After Primary Radiation Therapy for N2-N3 Head-and-Neck Cancer Stratified by HPV Status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 1078-1085.	0.4	100
155	Validation of a one-page patient-reported Charlson comorbidity index questionnaire for upper aerodigestive tract cancer patients. <i>Oral Oncology</i> , 2013, 49, 407-412.	0.8	36
156	A Randomized Controlled Trial of Lorazepam to Reduce Liver Motion in Patients Receiving Upper Abdominal Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 881-887.	0.4	8
157	Response to Letter to the Editor with Reference to article "Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure". <i>Oral Oncology</i> , 2013, 49, e19.	0.8	1
158	Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: Patterns of failure. <i>Oral Oncology</i> , 2013, 49, 255-260.	0.8	49
159	Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. <i>Oral Oncology</i> , 2013, 49, 79-85.	0.8	239
160	Quality of life instruments for skull base pathology: Systematic review and methodologic appraisal. <i>Head and Neck</i> , 2013, 35, 1221-1231.	0.9	19
161	Deintensification Candidate Subgroups in Human Papillomavirus-Related Oropharyngeal Cancer According to Minimal Risk of Distant Metastasis. <i>Journal of Clinical Oncology</i> , 2013, 31, 543-550.	0.8	551
162	CLINICAL USE OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM CANCER CLINICAL TRIALS: PRELIMINARY RESULTS FROM A SURVEY OF ONCOLOGISTS. <i>Journal of Epidemiology and Community Health</i> , 2013, 67, e2.17-e2.	2.0	0

#	ARTICLE	IF	CITATIONS
163	Phase II Trial of Palliative Radiotherapy for Hepatocellular Carcinoma and Liver Metastases. <i>Journal of Clinical Oncology</i> , 2013, 31, 3980-3986.	0.8	94
164	Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type <i>K-RAS</i> Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2477-2484.	0.8	122
165	Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1631-1639.	0.8	672
166	Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 226-226.	0.8	0
167	Outcomes following stereotactic body radiotherapy for patients with Child-Pugh B/C hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 167-167.	0.8	0
168	Atypical Clinical Behavior of p16-Confirmed HPV-Related Oropharyngeal Squamous Cell Carcinoma Treated With Radical Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 276-283.	0.4	207
169	The Effect of Registration Volume Extent on Residual Errors Assessed Using Cone-Beam Computed Tomography in Radiation Treatment of Head and Neck Cancer. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2012, 43, 95-102.	0.2	1
170	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. <i>Radiotherapy and Oncology</i> , 2012, 103, 49-56.	0.3	167
171	Development of a disease-specific quality-of-life questionnaire for anterior and central skull base pathology—the skull base inventory. <i>Laryngoscope</i> , 2012, 122, 1933-1942.	1.1	33
172	Impact of p16 status on the QOL effects of chemoradiation for locally advanced oropharynx cancer: Results of TROG 02.02.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5571-5571.	0.8	1
173	An international study of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different cancer sites.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6002-6002.	0.8	1
174	A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS5600-TPS5600.	0.8	2
175	Does change in health-related quality of life (HRQoL) score predict survival? Analysis of a lung cancer RCT.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7607-7607.	0.8	0
176	Retrospective Study of Palliative Radiotherapy in Newly Diagnosed Head and Neck Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 958-963.	0.4	48
177	Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers. <i>Quality of Life Research</i> , 2011, 20, 653-664.	1.5	123
178	The development and validation of a quality-of-life questionnaire for head and neck cancer patients with enteral feeding tubes: the QOL-EF. <i>Supportive Care in Cancer</i> , 2011, 19, 1175-1182.	1.0	20
179	Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. <i>Supportive Care in Cancer</i> , 2011, 19, 1753-1760.	1.0	133
180	Patterns of Care in Elderly Head-and-Neck Cancer Radiation Oncology Patients: A Single-Center Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 46-51.	0.4	77

#	ARTICLE	IF	CITATIONS
181	Rectal Motion in Patients Receiving Preoperative Radiotherapy for Carcinoma of the Rectum. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 97-102.	0.4	41
182	Cognitive Functioning After Radiotherapy or Chemoradiotherapy for Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 126-134.	0.4	78
183	Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 587-599.	0.7	12
184	Patient Self-Reports of Symptoms and Clinician Ratings as Predictors of Overall Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1851-1858.	3.0	196
185	Interfraction and Respiratory Organ Motion During Conformal Radiotherapy in Gastric Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 53-59.	0.4	99
186	Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. <i>Cancer</i> , 2010, 116, 4023-4032.	2.0	27
187	Response rates for mailout survey-driven studies in patients with head and neck cancer. <i>Head and Neck</i> , 2010, 32, 1585-1591.	0.9	9
188	Cone-Beam CT Assessment of Interfraction and Intrafraction Setup Error of Two Head-and-Neck Cancer Thermoplastic Masks. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 949-955.	0.4	63
189	Tirapazamine, Cisplatin, and Radiation Versus Cisplatin and Radiation for Advanced Squamous Cell Carcinoma of the Head and Neck (TROG 02.02, HeadSTART): A Phase III Trial of the Trans-Tasman Radiation Oncology Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 2989-2995.	0.8	339
190	Point-of-care outcome assessment in the cancer clinic: Audit of data quality. <i>Radiotherapy and Oncology</i> , 2010, 95, 339-343.	0.3	105
191	Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 119-128.	0.7	83
192	Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases. <i>Journal of Clinical Oncology</i> , 2009, 27, 1585-1591.	0.8	424
193	Comparative Prognostic Value of HPV16 E6 mRNA Compared With In Situ Hybridization for Human Oropharyngeal Squamous Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 6213-6221.	0.8	289
194	Making better use of existing cancer data: Patient Reported Outcomes and Behavioural Evidence: a new international initiative. <i>European Journal of Cancer Care</i> , 2009, 18, 105-107.	0.7	8
195	Truths and Myths About Radiotherapy for Verrucous Carcinoma of Larynx. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1110-1115.	0.4	39
196	Locoregional control remains a critical issue in gastric cancer. <i>Gastric Cancer</i> , 2008, 11, 64-65.	2.7	0
197	Esthesioneuroblastoma: The Princess Margaret Hospital experience. <i>Head and Neck</i> , 2008, 30, 1607-1614.	0.9	93
198	Adjuvant Therapy for Resected Gastric Cancer—Rapid, Yet Incomplete Adoption Following Results of Intergroup 0116 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1073-1080.	0.4	45

#	ARTICLE	IF	CITATIONS
199	Effect of Concurrent High-Dose Cisplatin Chemotherapy and Conformal Radiotherapy on Cervical Esophageal Cancer Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 735-740.	0.4	66
200	Stage-Specific Effect of Adjuvant Therapy Following Gastric Cancer Resection: a Population-based Analysis of 4,041 Patients. <i>Annals of Surgical Oncology</i> , 2008, 15, 500-507.	0.7	48
201	Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: Quality of life in a prospective phase I/II trial. <i>Radiotherapy and Oncology</i> , 2008, 87, 181-187.	0.3	40
202	A dose escalation study of hyperfractionated accelerated radiation delivered with integrated neck surgery (HARDWINS) for the management of advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 173-180.	0.3	28
203	Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus. <i>Radiotherapy and Oncology</i> , 2008, 89, 287-291.	0.3	132
204	Evaluation of Quality of Life and Organ Function in Head and Neck Squamous Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 1239-1256.	0.9	32
205	Lack of influence of intravenous contrast on head and neck IMRT dose distributions. <i>Acta Oncologica</i> , 2008, 47, 90-94.	0.8	25
206	Interpreting clinically significant changes in patient-reported outcomes. <i>Cancer</i> , 2007, 110, 196-202.	2.0	237
207	Intraobserver and Interobserver Variability in GTV Delineation on FDG-PET-CT Images of Head and Neck Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 763-770.	0.4	121
208	Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: Effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 709-716.	0.4	106
209	In reply to Dr. Cheng. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 311-312.	0.4	1
210	Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 713-719.	0.4	45
211	Postradiotherapy quality of life for head-and-neck cancer patients is independent of xerostomia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1403-1407.	0.4	55
212	Error in the delivery of radiation therapy: Results of a quality assurance review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1590-1595.	0.4	145
213	IMRT for adjuvant radiation in gastric cancer: A preferred plan?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 732-738.	0.4	94
214	Survey of computer use for health topics by patients with head and neck cancer. <i>Head and Neck</i> , 2005, 27, 8-14.	0.9	23
215	Primary radical external beam radiotherapy of rectal adenocarcinoma: Long term outcome of 271 patients. <i>Radiotherapy and Oncology</i> , 2005, 77, 126-132.	0.3	81
216	Interpreting differences in quality of life: The FACT-H&N in laryngeal cancer patients. <i>Quality of Life Research</i> , 2004, 13, 725-733.	1.5	69

#	ARTICLE	IF	CITATIONS
217	Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1127-1136.	0.4	28
218	Outcome and toxicity of postoperative short course adjuvant radiation and chemotherapy following resection of adenocarcinoma of the rectum. <i>Acta Oncol<sup>3</sup>gica</i> , 2004, 43, 567-570.	0.8	3
219	Accuracy of ultrasound in localization of breast boost field. <i>Radiotherapy and Oncology</i> , 2004, 72, 61-66.	0.3	37
220	Results of radiotherapy for primary subglottic squamous cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1245-1250.	0.4	38
221	A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 9-13.	0.4	93
222	Local excision and postoperative radiotherapy for distal rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 50, 1309-1316.	0.4	60
223	A structured review of quality of life instruments for head and neck cancer patients. <i>Head and Neck</i> , 2001, 23, 201-213.	0.9	165
224	Quality of life and utility in irradiated laryngeal cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 875-881.	0.4	26